Background: Treatment of the COVID19 pandemic requires drug development. Boron- containing compounds are attractive chemical agents, some of them act as proteases inhibitors.
Objective: The present study explores the role of boronic moieties in molecules interacting on the binding site of the SARS-CoV-2 main protease.
Methods: Conventional docking procedure was applied by assaying boron-free and boron-containing compounds on the recently reported crystal structure of SARS-CoV-2 main protease (PDB code: 6LU7). The set of 150 ligands includes bortezomib and inhibitors of coronavirus proteases.
Results: Most of the tested compounds share contact with key residues and pose on the cleavage pocket. The compounds with a boron atom in their structure are often estimated to have higher affinity than boron-free analogues.
Conclusion: Interactions and the affinity of boron-containing peptidomimetics strongly suggest that boron-moieties increase affinity on the main protease, which is tested by in vitro assays. A Bis-boron-containing compound previously tested active on SARS-virus protease and bortezomib were identified as potent ligands. These advances may be relevant to drug designing, in addition to testing available boron-containing drugs in patients with COVID19 infection.
[http://dx.doi.org/10.1016/j.toxlet.2016.06.018] [PMID: 27329537]
[http://dx.doi.org/10.2174/0929867326666190327154954] [PMID: 30919770]
[http://dx.doi.org/10.2174/1568026620999200305145032] [PMID: 32133962]
[http://dx.doi.org/10.2174/0929867325666180926150403] [PMID: 30259808]
[http://dx.doi.org/10.1021/acs.jmedchem.5b01461] [PMID: 26878082]
[http://dx.doi.org/10.1007/s00249-018-1336-9] [PMID: 30386878]